Literature DB >> 8927033

In vitro and in vivo antineoplastic effects of orthovanadate.

T F Cruz1, A Morgan, W Min.   

Abstract

In the present study we have demonstrated that orthovanadate at concentrations of 5-10 uM is cytotoxic to proliferating cells including primary cultures and tumour cell lines. However, concentrations of up to 50 uM did not affect the viability of non-proliferating cells. The cytotoxicity appears to be dependent on the vanadium concentration rather than on the oxidation state of vanadium or the vanadium compound. Furthermore, tumour cell lines with different proliferative rates were equally sensitive to orthovanadate cytotoxicity. Although the mechanisms responsible for the cytotoxicity are not known, addition of H2O2 potentiated orthovanadate cytotoxicity suggesting that hydroxyl or vanadium radicals may be involved. In vivo subcutaneous injections of orthovanadate into mice containing MDAY-D2 tumours resulted in the inhibition of tumour growth by 85-100%. These data indicated that orthovanadate at concentrations greater than 5 uM has antineoplastic properties and may be useful as a chemotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8927033     DOI: 10.1007/bf01075933

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

1.  Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia.

Authors:  M A Barry; C A Behnke; A Eastman
Journal:  Biochem Pharmacol       Date:  1990-11-15       Impact factor: 5.858

Review 2.  Use of vanadate as protein-phosphotyrosine phosphatase inhibitor.

Authors:  J A Gordon
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

Review 3.  Role of superoxide dismutase in cancer: a review.

Authors:  L W Oberley; G R Buettner
Journal:  Cancer Res       Date:  1979-04       Impact factor: 12.701

Review 4.  Free radicals, antioxidant enzymes, and carcinogenesis.

Authors:  Y Sun
Journal:  Free Radic Biol Med       Date:  1990       Impact factor: 7.376

5.  Hydroxyl radical generation in the NADH/microsomal reduction of vanadate.

Authors:  X Shi; N S Dalal
Journal:  Free Radic Res Commun       Date:  1992

6.  Dietary vanadyl(IV) sulfate inhibits chemically-induced mammary carcinogenesis.

Authors:  H J Thompson; N D Chasteen; L D Meeker
Journal:  Carcinogenesis       Date:  1984-06       Impact factor: 4.944

7.  Induction of neoplastic progression in Syrian hamster embryo cells treated with protein phosphatase inhibitors.

Authors:  C A Afshari; S Kodama; H M Bivins; T B Willard; H Fujiki; J C Barrett
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

8.  Lipocortin 2 (annexin 2) is a major substrate for constitutive tyrosine kinase activity in chondrocytes.

Authors:  D T Grima; R A Kandel; B Pepinsky; T F Cruz
Journal:  Biochemistry       Date:  1994-03-15       Impact factor: 3.162

9.  Orthovanadate both mimics and antagonizes the transforming growth factor beta action on normal rat kidney cells.

Authors:  G Rijksen; M C Völler; E J Van Zoelen
Journal:  J Cell Physiol       Date:  1993-02       Impact factor: 6.384

10.  Activation of mitogen activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation.

Authors:  F D'Onofrio; M Q Le; J L Chiasson; A K Srivastava
Journal:  FEBS Lett       Date:  1994-03-07       Impact factor: 4.124

View more
  11 in total

1.  Vanadium and diabetes. What about vanadium toxicity?: A reply.

Authors:  J H McNeill
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

Review 2.  Anti-diabetic and toxic effects of vanadium compounds.

Authors:  A K Srivastava
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

Review 3.  Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling.

Authors:  I G Fantus; G Deragon; R Lai; S Tang
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

Review 4.  Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects.

Authors:  I G Fantus; E Tsiani
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.396

5.  Vanadate activated Akt and promoted S phase entry.

Authors:  Zhuo Zhang; Ning Gao; Hengjun He; Chuanshu Huang; Jia Luo; Xianglin Shi
Journal:  Mol Cell Biochem       Date:  2004-01       Impact factor: 3.396

6.  New vanadium-based magnetic resonance imaging probes: clinical potential for early detection of cancer.

Authors:  Devkumar Mustafi; Bo Peng; Sean Foxley; Marvin W Makinen; Gregory S Karczmar; Marta Zamora; John Ejnik; Heather Martin
Journal:  J Biol Inorg Chem       Date:  2009-07-02       Impact factor: 3.358

7.  The mitogen-activated protein kinase pathway contributes to vanadate toxicity in vascular smooth muscle cells.

Authors:  G Daum; B Levkau; N L Chamberlain; Y Wang; A W Clowes
Journal:  Mol Cell Biochem       Date:  1998-06       Impact factor: 3.396

8.  Real-time Analysis of Impedance Alterations by the Effects of Vanadium Pentoxide on Several Carcinoma Cell Lines.

Authors:  Ebru Öztürk; Ayşe Kübra Karaboğa Arslan; Alim Hüseyin Dokumaci; Mükerrem Betül Yerer
Journal:  Turk J Pharm Sci       Date:  2018-04-02

9.  (E)-N'-{7-Meth-oxy-spiro-[chromeno[4,3-d]thia-zole-4,1'-cyclo-hexa-n]-2-yl}-N,N-dimethyl-acetimidamide.

Authors:  Kamini Kapoor; Vivek K Gupta; Rajni Kant; Poorvesh M Vyas; Mihir J Joshi; Kalpesh M Menpara; Kartik D Ladva
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-10-05

10.  A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice.

Authors:  J K Jackson; W Min; T F Cruz; S Cindric; L Arsenault; D D Von Hoff; D Degan; W L Hunter; H M Burt
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.